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Abstract
Given the widespread use of psychotropic drugs in the population, it’s important to 
consider hyponatremia as an avoidable and reversible adverse effect and include the 
detection of high-risk subjects to establish safer medications, as well as early detection 
measures in routine clinical practice. Although hyponatremia has been especially associ-
ated with serotonergic antidepressants (SSRIs), there is also an elevated risk with tricy-
clics, duals and heterocyclic antidepressants, due to the different mechanisms of action 
at the renal tubular level and the release of ADH. Hyponatremia secondary to tricyclics 
with slow CYP2D6 metabolizers have higher plasma concentrations of antidepressants 
metabolized by CYP2D6. Hyponatremia secondary to SSRIs appears in the first week of 
treatment, it is “not dose-dependent” and normalization of natremia occurs between 2 
and 20 days after stopping the medication. Bupropion, trazodone, mianserin, reboxetine 
and agomelatine are a safe alternative. Also antiepileptics have been related to hypona-
tremia. Both typical and atypical antipsychotics have been exposed to an increased risk of 
hyponatremia, even after adjusted factors such as age, sex and comorbidity. Other factors 
that favor the onset of hyponatremia act synergistically with psychotropic drugs, such as: 
advanced age, female sex, concomitant diuretic intake, low body weight and low sodium 
levels; NSAID, ACEIs, and warm.
Keywords: hyponatremia, antipsychotic, antidepressant, antiepileptic, psychotropic 
drugs
1. Introduction
Hyponatremia is the most frequent hydroelectrolytic disorder in clinical practice, both in 
hospital and outpatient settings [1]. Defined as a serum sodium concentration or sodium 
level < 135 mmol/L, its frequency varies according to its intensity, with severe and more severe 
hyponatremia in hospitalized patients. Hyponatremia is present in 15–20% of urgent hospital 
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admissions and in up to 20% of critical patients. Although it estimates a daily incidence of 1% 
in hospitalized patients and a prevalence of 2.5%, its frequency is probably higher, since it is 
frequently underdiagnosed [2]. Some epidemiological studies report that only 30% of patients 
with hyponatremia are diagnosed, including the most serious ones [3]. Clinical manifesta-
tions of hyponatremia have a broad spectrum, from mild to severe or even potentially lethal. 
Hyponatremia is related to an increase in mortality, morbidity, duration of hospital stay and 
socio-health costs in patients with multiple pathologies. Some studies show that the presence 
of hyponatremia is an independent predictor of mortality rate, implying a relative risk of 
death between 1 and 2 times higher [4]; risk that is maintained per year and even 5 years after 
a hospital admission. Hyponatremia is related to a higher rate of hospitalization in Intensive 
Care Units and mechanical ventilation units.
Etiology of hyponatremia is multifactorial, highlighting the pharmacological origin. Some 
of the mechanisms involved in the development of pharmacological hyponatremia are the 
alteration of sodium and water homeostasis (diuretics), the increase in the production of 
the antidiuretic hormone (antidepressants, antipsychotics, antiepileptics, anticancer drugs, 
methrotrexate, interferon alfa, opiates) and the potentiation of the effects of antidiuretic 
hormone (antiepileptic, hypoglycemic, nonsteroidal anti-inflammatory drugs [NSAIDs], 
angiotensin-converting enzyme inhibitors [ACEIs] and anticancer drugs). Factors such as 
female sex, weight, advanced age, the presence of associated pathologies (cardiological, 
hepatic, neurological and endocrine), the concomitant use of drugs (especially thiazide 
diuretics, inhibitors of the reuptake of serotonin and carbamazepine) and basal sodium 
levels in the low threshold of normality have been related to the development of hypona-
tremia [5].
Prescription and use of psychotropic drugs is currently growing, both due to the increase in 
the incidence of mental illnesses and depression, which according to the WHO will be the 
second cause of disability in the world in 2020 [6]. Elderly patients have higher prevalences of 
mood disorders, which together with the greater frequency of polypathology and polyphar-
macy, makes them a risk group for presenting hyponatremia.
2. Hyponatremia
2.1. Definition of hyponatremia
2.1.1. Definition of hyponatremia based on biochemical severity
Mild (sodium between 130 and 135 mmol/L); moderate (sodium between 125 and 129 mmol/L); 
severe (sodium <125 mmol/L).
2.1.2. Definition of hyponatremia based on development time
Acute (<48 h) or chronic (greater or equal to 48 h). Current literature establishes the limit of 
48 h to distinguish between acute and chronic hyponatremia, since cerebral edema appears 
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more frequently when hyponatremia is established in less than 48 h. Experimental studies 
suggest that the brain needs approximately 48 h to adapt to a hypotonic environment; there is 
a risk of cerebral edema before such adaptation. However, once the adaptation is completed, 
a rapid rise in the serum sodium level can cause lesions of the myelin sheath, which is known 
as osmotic demyelination syndrome. Hence, the importance in clinical practice to distinguish 
between acute and chronic hyponatremia, evaluating whether a subject is at greater risk of 
cerebral edema or osmotic demyelination. If there are doubts about the development time of 
hyponatremia [7], it should be considered chronic, unless there are reasons to think otherwise.
2.1.3. Definition of hyponatremia based on symptoms
Moderate: any degree of hyponatremia associated with moderately severe symptoms of 
hyponatremia: nausea without vomiting, confusion, and headache.
Severe: any biochemical degree of hyponatremia associated with severe symptoms of hyponatre-
mia: vomiting, cardiorespiratory distress, abnormal and deep drowsiness, seizures, and coma.
2.1.4. Definition of hyponatremia based on plasma osmolality
• Hypotonic hyponatremia: the decrease in extracellular sodium is accompanied by hypo-
tonia of the extracellular fluid and displacement of water from the extracellular space to 
the intracellular space, causing cellular edema. The most frequent cause is a syndrome of 
inappropriate secretion of antidiuretic hormone (SIADH). There are three types according 
to the volume status:
a. hypotonic hyponatremia with hypovolemia: occurs when there are losses of sodium and 
water, with partial supplementation of fluid losses without electrolytes. Losses can occur 
through the skin, digestive tract, renal pathway or leakage of fluids into a third space.
b. hypotonic hyponatremia with isovolemia: SIADH is the most common cause of hyponatremia.
c. hypotonic hyponatremia with hypervolemia: it occurs both in situations of increased 
vasopressin secretion in states of a relative decrease in effective intravascular volume 
(chronic heart failure, liver cirrhosis with ascites, nephrotic edema); excessive fluid 
intake without electrolytes and an altered excretion of free water (acute kidney injury, 
advanced chronic kidney disease).
• Nonhypotonic hyponatremia (isotonic or hypertonic): increase in the plasma concen-
tration of effective osmoles displaces the water from the intracellular to the extracellular 
space and generates a dilutional hyponatremia. Depending on the concentration of these 
compounds the plasma osmolality may be normal or increased. The most frequent cause 
is hyperglycemia.
• Fictional hyponatremia or pseudohyponatremia occurs when a plasma concentration of 
sodium falsely decreases as a result of a high concentration of lipids or paraproteins, with 
normal plasma osmolality.





Primary polydipsia, intensive physical exercise, thiazide diuretics, postoperative state, vaso-
pressin analogs, colonoscopy preparations, 3,4-methylenedioxymethamphetamine intake.
2.2.2. Nonhypotonic hyponatremia
• Isotonic or hypertonic: secondary to the presence of effective osmoles (glucose, mannitol, 
glycine, hyperosmolar radiological contrast, maltose).
• Isotonic or hyperosmolar: secondary to presence of ineffective osmoles that elevate measured 
serum osmolality but do not cause hyponatremia because they do not change effective 
osmolality and does not attract water to extracellular compartment (urea, alcohol).
• Isotonic: presence of endogenous solutes that cause pseudohyponatremia (triglycerides, 
cholesterol, proteins, intravenous immunoglobulins, monoclonal gammopathies).
2.2.3. Hypotonic hyponatremia
• Hypovolemic: excessive sweating, vomiting, diarrhea, digestive tract fistulas, diuretics, tubu-
lopathies, mineralocorticoid deficiency.
• Hypervolemic: chronic heart failure, liver cirrhosis, nephrotic edema, ascites, acute and chronic 
renal failure.
• Isovolemia: syndrome of inappropriate secretion of antidiuretic hormone (SIADH) which 
can be secondary to tumors (lung, oropharynx, stomach, duodenum, pancreas, ureter, 
bladder, prostate, endometrium, Ewing sarcoma, lymphomas, neuroblastoma), nervous 
system disorder (encephalitis, meningitis, abscess, infection by Rickettsia and Plasmodium, 
HIV, subdural hemorrhage, stroke, hydrocephalus, multiple sclerosis, Guillain-Barré 
syndrome, delirium tremens, acute porphyria), drugs (antidepressants, anticonvulsants, 
antipsychotics, anticancer drugs, antidiabetics, vasopressin analogs, opioids, interferon, 
NSAIDs, clofibrate, nicotine, proton pump inhibitors, amiodarone) [7].
2.2.4. Hyponatremia and psychotropic drugs
As we have previously described, in case of psychotropic drugs, hyponatremia is mediated 
by the inappropriate release of ADH. ADH or vasopressin is a hypothalamic hormone that 
is stored and released through the neurohypophysis in response to osmotic and nonosmotic 
stimuli:
1. Osmotic stimulus: the ADH is released or inhibited depending on the concentration of 
effective osmoles in the extracellular compartment. Osmotic threshold for ADH release is 
280 – 290 mOsm/kg.
2. Nonosmotic stimulus:
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• Hemodynamics. In the presence of low effective circulating volume, the baroreceptors 
are activated. For example: hypovolemia, liver cirrhosis, arterial hypotension, conges-
tive heart failure, nephrotic syndrome, primary adrenal insufficiency.
• Nonhemodynamic: mediated by the release of corticotropin-releasing hormone (CRH, 
neurotransmitter involved in the response to stress and responsible for activating the 
pituitary secretion of ACTH) and angiotensin II. For example: pain, stress, nausea and 
vomiting, hypoglycemia, drugs, cancer, postoperative state, pulmonary or central ner-
vous system pathology.
Vasopressin has three receptors coupled to G proteins: V1 (presents vasopressor effect), V2 
(responsible for the reabsorption of water in the collecting tubule of the nephron) and V3 
(responsible for the release of ACTH). Vasopressin or ADH has several functions:
1. Renal. ADH acts on V2 receptors on collecting duct in the nephron. Its action increases the 
reabsorption of water, but not of solute, through the increased expression of aquaporin 
2 channels (AQP2). Aquaporins are proteins that are part of the water channel. AQP2 is 
expressed exclusively in collecting duct principal cells and is responsible for the apical 
water permeability of this region of the nephron. Its activity is dependent on ADH, which 
is released in response to hyperosmolar and hypovolemic stimuli. There is a type of inher-
ited nephrogenic diabetes insipidus associated with mutations in AQP2 [8].
2. Vascular smooth muscle. It produces vasoconstriction and increases peripheral vascular 
resistance.
2.3. Symptomatology
The symptomatology of hyponatremia varies depending on the biochemical severity and the 
speed of the establishment. It can be classified as mild, moderate and severe.
2.3.1. Mild symptoms
(Na 130–135 mEq/L): headache, attention deficit, memory alterations, irritability, depression.
2.3.2. Moderate symptoms
(Na 120–130 mEq/L): nausea, vomiting, bradypsychia, confusion, disorientation.
2.3.3. Severe symptoms
(Na < 120 mEq/L): stupor, seizures, coma, respiratory depression.
2.3.4. Hyponatremic encephalopathy
In hyponatremia, low serum osmolarity causes an osmotic gradient between the extracellular 
space and the intracellular space, with the consequent passage of free water into the interior 
of the cell. This accumulation of water in the brain cells causes cerebral edema. The cellular 
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edema produces an increase in the size of the various organs, however in the case of brain, 
expansion is not possible due to the limitation of the cranial cavity. Thus, increases in brain 
volume of 8–10% can cause coma and compromise the condition of the individual due to 
intracranial hypertension and transtentorial herniation. However, hyponatremia activates a 
series of compensatory mechanisms to decrease the volume of intracellular fluid, to reduce 
the risk of cerebral edema and the risks derived from it [9]. Adequate regulation of brain 
volume is an essential factor in the prognosis of hyponatremic encephalopathy. Some of these 
compensatory mechanisms are:
1. The increase in intracranial pressure favors the increase of hydrostatic pressure and subse-
quent passage of water to the ventricular and venous system.
2. After an initial osmotic edema, the cells quickly expel electrolytes (potassium, chloride 
and sodium) into the extracellular space, with the subsequent release of water by osmotic 
gradient, restoring brain volume. This phenomenon allows to restore cell volume in hours 
but is energy dependent and requires the operation of sodium-potassium ATPase system.
3. Role of the astrocytes. Act as regulators of brain water content, its swelling in hyposmolar 
situations protect and spare neurons. Its extensions form the blood-brain barrier and they 
have high number of pores called aquaporins (AQP) particularly AQP1 and AQP4, allow-
ing the passage of water into astrocytes in hyposmolar situations which selectively swell, 
whereas neurons are relatively spared.
4. Studies in animals have shown that brain osmolytes (glycine, taurine, creatine myo-
inositol) leave the cell in hypoosmolar states and accumulate in the hyperosmolar states. 
Studies in humans with magnetic resonance imaging show that the osmolytes output is 
parallel to the changes in sodium concentration, which takes approximately 48 h.
Brain adaptation to hyponatremia is related to the speed of its establishment. In chronic hypo-
natremia (that lasts more than 48 h) the slow and progressive decrease of sodium allows a 
compensatory regulation of the whole volume, limiting the degree of cerebral edema and 
being asymptomatic or slightly symptomatic. However, in cases of acute hyponatremia, 
adaptive mechanisms are exceeded and symptoms are more likely to occur even with mild 
hyponatremia.
There are some risk factors for the development of hyponatremic cerebral edema:
• Menstruating women. Estrogens inhibit the sodium-potassium ATPase, making intracel-
lular sodium leakage difficult; and affect the expression of AQP4 channels. In this patient 
profile, cases of hyponatremic encephalopathy with cerebral herniation have been docu-
mented even with serum sodium of 128 mEq/L.
• Children. They are a risk group for unfavorable evolution in hyponatremic encephalopa-
thy. It is postulated that the high ratio of brain size to that of the skull after the closure of 
the fontanelles, as well as the lower activity of the sodium-potassium ATPase pump than in 
adults can limit the adaptation to cerebral edema.
Fluid and Electrolyte Disorders38
• Hypoxia It has been postulated that hypoxia is a factor for death and brain damage in 
patients with hyponatremia, after adjustment for other comorbidities. It alters the regu-
lation of the energy-dependent astrocyte volume, since the active transport of sodium 
requires oxygen. In addition, in patients with hyponatremic encephalopathy, cranial 
hypertension and incipient brain herniation may favor the development of a neurogenic 
pulmonary edema and hypercapnic respiratory failure that worsens hypoxia.
• Hormonal factors: vasopressin and estrogen make it difficult to adapt to cellular edema. 
On the one hand, vasopressin acts by decreasing brain flow and oxygen consump-
tion through arterial vasoconstriction, as well as facilitating the displacement of water 
in brain cells through AQP4. On the other hand, estrogens increase the secretion of 
vasopressin.
• Risk factors to develop hyponatremia: as we have previously commented, the establish-
ment of the hyponatremia and the severity of it is associated with multiple factors such as 
polypathology and polymedication, among others. For this reason, literature recommends 
the identification of those risk factors to perform an adequate prevention and early detec-
tion of those cases of hyponatremia.
2.3.5. Age
Elderly patients are a vulnerable population and at risk of developing hyponatremia due to 
various causes. In the first place, the physiological changes characteristic of aging, such as 
the decrease in volume and body weight, pose a risk to develop hyponatremia. On the other 
hand, they are a population often with multi co-morbidities, exposed to diets without salt, to 
forced hydration (oral or intravenous) and with the use of polytherapy, which makes them 
candidates for risk.
2.3.6. Institutionalization
Some studies have shown a higher incidence of hyponatremia in subjects older than 60 years 
institutionalized in residences than in patients of the same age living at home (18 versus 8%) [10].
2.3.7. Female sex
Female sex has been associated with an increased risk of hyponatremia and the development 
of hyponatremic encephalopathy [11]. Some hypothesis proposed for this difference are based 
on hormonal factors and cellular transport of sodium and volume of distribution of body 
water different from men.
2.3.8. Comorbidity
Hyponatremia has been associated with multiple pathologies (infectious, oncological, neuro-
logical, renal, metabolic, etc.).




Multiple drugs have been associated with an increased risk of hyponatremia, especially anti-
psychotics, antidepressants and antiepileptic [12], diuretics (mainly thiazides), ACEIs and 
NSAIDs. Other drugs have been related to hyponatremia, such as vasopressin analogs, inter-
feron, antidiabetics, anticancer drugs, proton pump inhibitors and monoclonal antibodies, 
among others.
1. Basal levels of sodium in low range of normality
2. Low weight
3. Exposure to high temperatures
2.4. Treatment
It is important to remember that despite of the severity of the neurological signs and symp-
toms of acute hyponatremia, the correction of hyponatremia in a rapid and uncontrolled 
way can generate chronic neurological lesions due to osmotic demyelination. When there is 
a decrease in sodium, cells excrete organic solutes and other molecules to maintain homeosta-
sis, in a process that can last between 48 and 72 h, so hyponatremia can be classified as acute 
or chronic if the duration is shorter or greater than 48 h, respectively.
It is recommended that sodium correction rate does not exceed 8 mmol/L in any 24-h period, 
being even lower in those patients susceptible to osmotic demyelination (as in the case of 
advanced cirrhosis, alcoholism or severe malnutrition). Even in patients with severe hypo-
natremia that are accompanied by severe neurological symptoms, 4 – 6 mEq/L rise in serum 
sodium is sufficient in the first 24-h (this target can be achieved in first few hours in severely 
symptomatic patients and then maintained at that level for the first 24-h). Three percent 
sodium chloride solution can be used to achieve this. It is important to remember that the 
recommended correction rates of 24 h should not be exceeded.
There is a series of formulas that allow to calculate in a quantitative way the effect of the 
prescribed fluid therapy on patient’s serum sodium.
The Adrogue-Madias Formula (AMF) [13] helps to estimate the effect of a given fluid on 
serum sodium. It takes into account the sodium concentration and the total body weight 
(TBW) adjusted by a correction factor that varies according to age and sex. However, the 
AMF does not take into account the losses and the pathophysiology that underlies them and 
requires that sodium levels be monitored frequently during the infusion of the fluid.
Infusate formula: Adrogue-Madias formula.
  (1)
However, this formula has the limitation of being approximate as rise in sodium level is often 
greater than that predicted by the formula.
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Fluid restriction should be the first therapeutic measure in cases of euvolemic or hypervol-
emic hyponatremia. Depending on the severity of the hyponatremia and symptomatic sever-
ity, the fluid should be restricted to provide a negative fluid balance of approximately 500 ml 
per day.
There are several therapeutic options for the treatment of hyponatremia secondary to SIADH:
Demeclocycline. It is a tetracyclic antibiotic whose mechanism of action is the inhibition 
of ADH receptors in the renal distal tubule, inducing nephrogenic diabetes insipidus. It is 
administered in doses of (300 – 600 mg twice a day). Side effects include photosensitivity, 
nephrotoxicity and nausea.
Antagonists of the vasopressin receptor (“vaptans”). ADH or vasopressin acts at the level 
of various receptors: V1a (causes vasoconstriction), V1b (secretion of ACTH) and V2 (water 
reabsorption and release of von Willebrand factor and factor VIII). Drugs that act on V2 recep-
tors at the tubular level increase the excretion of water (aquaresis).
• Tolvaptan: It has an action as a selective antagonist of the V2 receptors of vasopressin at 
the level of the renal tubule, increasing the free elimination of water. It has been used in 
patients with congestive heart failure, cirrhosis and SIADH. Although it has not shown 
a reduction in the rates of rehospitalization or death due to congestive heart failure, it 
improves sodium levels, fluid balance and symptoms of congestion. It is approved for the 
treatment of hypervolemic and euvolemic hyponatremia.
• Conivaptan: Antagonist of the V1a-V2 receptors with approval for the treatment of 
euvolemic and hypervolemic hyponatremia. Its use is limited to intravenous use at the 
hospital level.
• Lixivaptan: V2 receptor antagonist of vasopressin, used in euvolemic and hypervolemic 
hyponatremia.
3. Hyponatremia and antipsychotics
Antipsychotics are a family of drugs used primarily in the treatment of schizophrenia, bipolar 
disorder and other affective psychoses, but also in other neuropsychiatric disorders (such 
as dementia and autism), symptomatic treatment of acute confusional symptoms and other 
conditions not psychiatric (nausea, hiccups, migraine). Some studies show stability in the 
prevalence (2.05%) and incidence (0.66%) in the use of antipsychotics in the last decade, 
although showing an increase in its use in the infant-juvenile population and higher employ-
ment of second generation antipsychotics (SGAPs) [14]. Its mechanism of action is dopami-
nergic blocking. They are classified into two main groups: the classic or typical antipsychotics, 
which present a blockade of the D2 dopaminergic receptor and are effective in the positive 
symptoms of schizophrenia (hallucinations and delusions) but show extrapyramidal symp-
toms as the most notable side effects; and the atypical or second generation antipsychotics, 
in addition to blocking the D2 receptor, exhibit muscarinic, adrenergic, serotonergic and 
histamergic receptor activity, showing a broader spectrum of action (including positive and 
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negative symptoms) and a different side effect profile of the typical ones (minor extrapyra-
midal symptoms, but weight gain, dry mouth, orthostatic hypotension, constipation, urinary 
retention, narrow-angle glaucoma, sedation).
Hyponatremia is an adverse effect described both in the case of classical and atypical anti-
psychotics. It is postulated that the etiopathogenesis of hyponatremia in atypical antipsy-
chotics is mediated by the action of serotonin, both by the release of ADH induced by the 
stimulation of central receptors 5-HT2 and 5-HT1c and by the increase in the effects of ADH 
at the renal medullary level [15]. In the case of typical antipsychotics, prolonged blockade of 
dopamine D2 receptors stimulates the release of ADH and increases its peripheral response 
[16]. The occurrence of hyponatremia occurs in the first 3 weeks of treatment in up to 50% of 
cases, although cases have also been reported in patients undergoing long-term chronic treat-
ments. On the other hand, in the case of antipsychotics, neither age nor female sex are risk 
factors. The chemical structure and receptor affinity profiles of the dopamine D2 receptor and 
serotonin 5-HT2A have not shown a variation with respect to the risk of hyponatremia [17]. 
Several studies describe that hyponatremia at admission is associated with greater medical 
deterioration in hospitalized psychiatric patients [18], therefore adequate clinical monitoring 
should be performed to identify and treat somatic pathologies and concomitant use of drugs. 
Also, it is recommended to measure serum sodium in those patients on antipsychotic treat-
ment who present with seizures.
In a follow-up study over 15 years with a sample of 2051 patients diagnosed with schizophrenia 
[19] from 1998 to 2013, an incidence of hyponatremia of 6.7% was observed. The study showed 
that the use of antipsychotics, both typical and atypical, was associated with an elevated risk 
of hyponatremia with respect to the nonuse of antipsychotics, even after adjusting for age, sex 
and physical comorbidity. Age of diagnosis of the disease, low income, physical comorbidity, 
psychiatric admissions and concomitant treatment with carbamazepine were also associated 
with an increased risk of hyponatremia. Another retrospective study showed that treatment 
with atypical antipsychotics in the elderly was associated with a modest but statistically sig-
nificant increase in the risk of hospitalization for hyponatremia in 30 days, an association that 
was smaller than other psychotropic drugs [20]. A systematic review on hyponatremia and 
the use of antipsychotics, published in 2010 [16], which includes 4 studies and 91 cases and 
series of cases, showed that the diagnosis of schizophrenia and male sex were more frequently 
associated with hyponatremia. Using the Naranjo Scale of Adverse Drug Reaction Probability 
Scale, in 80% of the cases possible causality was determined, in 19% probable causality and in 
1% impossible causality. No significant association was found between daily doses of drugs 
and serum sodium or time to onset of hyponatremia. Currently, tolvaptan is positioned as a 
drug approved by the FDA in the treatment of euvolemic and hypervolemic hyponatremia, 
and useful in the management of hyponatremia associated with the use of antipsychotics [21].
3.1. First generation antipsychotics (FGAS)
In recent decades the use of typical antipsychotics has been progressively replaced by atypical 
ones, by the receptor profile and side effects. Nonetheless, haloperidol continues to be the 
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drug of choice in the management of agitation and acute confusional syndrome. Haloperidol-
related hyponatremia has been reported for decades [22, 27], but also with other first-gen-
eration antipsychotics such as chlorpromazine, perphenazine, and fluphenazine  [23–25]. In 
the majority of cases there were other intercurrent factors involved in the development of 
hyponatremia (concomitant treatment with ACE inhibitors, diuretics and other psychotropic 
drugs).
3.2. Second generation antipsychotics (SGAS)
3.2.1. Aripiprazole
Aripiprazole is a partial agonist of dopamine, frequently used for its efficacy in cognitive and 
affective symptoms in psychosis. There are currently presentations for oral, parenteral and 
prolonged release treatment. Literature collects cases of aripiprazole-induced hyponatremia 
both in patients who developed the symptoms at the start of treatment [15] and in increasing 
the dose [26], improving in all of them the clinical symptoms with interruption of treatment 
and water restriction.
3.2.2. Olanzapine
It is an atypical antipsychotic, antagonist of D2 and 5HT2A receptor. It is commonly used 
in clinical practice to control agitation and positive symptoms. Cases of olanzapine-induced 
hyponatremia have been reported together with the concomitant use of other psychoactive 
drugs [5, 27]. In 2014, a case of death was described in a young schizophrenic male who 
presented with hyponatremia secondary to excessive water intake and which was related to 
the increase in the dose of olanzapine, which could have acted aggravating the intoxication 
itself [28].
3.2.3. Quetiapine
Synthesized in 1985, it is used in the treatment of schizophrenia, bipolar disorder, Alzheimer’s 
disorder and major depression. There are few cases of SIADH induced by quetiapine, 
something that could be related to underdiagnosis and underreporting of this situation. 
Nonetheless, some cases are collected where quetiapine, together with other factors such as 
advanced age and polytherapy, is involved in the development of hyponatremia [29–31].
3.2.4. Risperidone
Approved by the FDA in 1993 for the use of schizophrenia, exists in oral presentation and 
depot. Like the other antipsychotics, risperidone has also been associated with the risk of 
developing hyponatremia, although some cases have been described in which the use of ris-
peridone improved polydipsia in the schizophrenic patient [32, 33]. However, the results in 
the literature are inconclusive and controversial regarding the improvement of certain atypi-
cal antipsychotics (olanzapine and risperidone) on primary polidipsia.




Paliperidone is an active metabolite of risperidone, indicated in the management of schizo-
phrenia and schizoaffective disorder. In 2016, a case of rhabdomyolysis, malignant neuro-
leptic syndrome and SIADH associated with paliperidone prolonged release in a 35-year-old 
man hospitalized for psychotic decompensation was described. Two days after the adminis-
tration of the treatment, the patient presented with a tonic-clonic seizure that was attributed 
to hypoosmolar hyponatremia [34]. It is important to remember that in all patients receiv-
ing antipsychotic treatment, serum sodium should be measured in the presence of epileptic 
seizures.
3.2.6. Ziprasidone
Ziprasidone is an atypical antipsychotic indicated in psychotic agitation, schizophrenia and 
manic and mixed episodes in bipolar disorder. The literature includes a series of cases in 
which hyponatremia is observed in the context of the use of ziprasidone, concomitantly with 
other psychopharmaceuticals such as duloxetine [35] and with comitial symptoms in the 
debut of the hyponatremia [36], as a neurological symptom present in cases of hyponatremia.
3.2.7. Clozapine
Synthesized in the late 1950s, clozapine is considered the first atypical antipsychotic. It empha-
sizes its low rate of extrapyramidal effects and its antipsychotic potency, being currently 
indicated in the management of resistant psychosis and psychotic symptoms in Parkinson’s 
disease. Literature collects controversial data on its relationship with hyponatremia, although 
some authors defend its use in Syndrome of Psychosis, Intermittent Hyponatremia and 
Polydipsia (PIP syndrome) [37].
3.3. Syndrome of psychosis, intermittent hyponatremia and polydipsia (PIP 
syndrome)
Hyponatremia in psychotic patients is a relatively frequent complication, both due to the 
osmotic dysregulation of the disease and the secondary effect of antipsychotics. The PIP 
syndrome is characterized clinically by the presence of acute confusional symptoms derived 
from symptomatic hyponatremia and water intoxication. Between 6 and 20% of psychotic 
patients presents with polydipsia. In psychotic patients, in addition to xerostomia and con-
sequent compulsive water intake, the role of supra-optic and paraventricular hypothalamic 
nuclei, responsible for the regulation of thirst and secretion of antidiuretic hormone (ADH) 
in the pathophysiology of hyponatremia, is postulated, as well as dopamine and endogenous 
opioids as neurotransmitters involved in the ingestion of water. Neuroimaging studies in 
schizophrenic patients show a ventricular dilation in basal conditions, however under condi-
tions of hyponatremia cerebral edema and ventricular contraction are observed. Some studies 
show that the MDR1 C3435T polymorphism may increase the susceptibility to polydipsia in 
schizophrenia [38].
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Despite its prevalence, morbidity and mortality, it is an underestimated entity in its preven-
tion and early diagnosis. One of the diagnostic challenges is the differentiation between hypo-
natremia induced by antipsychotics and PIP, since often the treatment of one of the entities 
worsens the other. Some studies show that urine concentration measurements are useful to 
differentiate both situations, detecting more frequently concentrated urine in pharmacologi-
cal hyponatremia and dilute urine secondary to psychotic decompensation [39]. While some 
studies show that clozapine can generate polydipsia and hyponatremia, others show that it 
improves the symptoms of polydipsia, so clozapine is postulated as a therapeutic option [37], 
especially as an alternative to electroconvulsive therapy in cases of catatonia [40].
4. Antidepressants
The consumption of antidepressants has increased significantly in most Organization for 
Economic Co-operation and Development (OECD) countries since the year 2000. There is 
significant variation in consumption of antidepressants between countries. For example, in 
Germany, antidepressant use had risen 46% in just 4 years, in case of Spain and Portugal, it 
rose about 20% during the same period and Iceland led the pack in overall use with about 
one in 10 people taking a daily antidepressant [41]. The new generation of antidepressant 
drugs are widely used as the first line of treatment for major depressive disorders and are 
considered to be safer than tricyclic agents due to a profile of better tolerability and lower rate 
of side effects [42]. Several side effects are transient and may disappear after a few weeks fol-
lowing treatment initiation, but potentially serious adverse events may persist or ensue later.
Hyponatramia is the most common electrolyte disorder in ambulatory outpatients, especially 
in the elderly, and is one of the many well-known side effects of antidepressants [43]. Most 
of the evidence pointing toward an increased risk of hyponatremia with the use of antide-
pressant medications is based on multiple case reports and a few observational studies. It 
is important to remember that mild hyponatremia is associated with instability and falls, 
reduced cognitive function, osteoporosis and increased morbidity and mortality [44]. Most 
studies are small and observational and only few have had the power to examine whether 
specific antidepressants carry a higher or lower risk of hyponatremia.
Hyponatremia, usually, is not dose dependent and the patient recovers when treatment with 
antidepressant is interrupted. For this reason, early detection as well as the evaluation of 
concomitant risk factors in all patients starting antidepressant are important. Besides, it seems 
necessary to supervise sodium plasma levels periodically when patients are in treatment with 
antidepressants and to choose safe drugs between all possibilities [45].
The selective serotonin reuptake inhibitors (SSRIs) and venlafaxine appear to be the antide-
pressants most commonly associated with hyponatremia. Between the SSRIs, the inci-
dence of hyponatremia varies based on the definition of hyponatremia used. On the one 
hand, studies which defined hyponatremia as serum sodium levels <135 mmol/l, the inci-
dence ranged from 9 to 40%. On the other hand, the incidence decreased to 0.06–2.6% when 
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hyponatremia was defined as serum sodium levels <130 mmol/l. The number of case reports 
and small observational studies with hyponatremia concerning SSRI is substantially higher 
than the number of case reports and observational studies with other antidepressants, but it 
is not clear whether this is due to a true difference in incidence of hyponatremia. A review 
concluded that current evidence suggests a relatively higher risk of hyponatremia with SSRIs 
and venlafaxine compared to tricyclic antidepressants (TCA) and mirtazapine, but for several 
antidepressants, data were insufficient to determine the risk of hyponatremia [46]. We found 
that there were no consistent difference in the incidence of hyponatremia among different 
SSRI members, but available data indicate that the incidence could be slightly higher for 
citalopram, fluoxetine and escitalopram, whereas incidence rates may be lower for sertraline 
and paroxetine [47–49].
Nevertheless, according to national and international pharmacovigilance committees, 1/3 of 
the reports of drug induced hyponatremia are severe, with the greatest frequency involving 
paroxetine, fluoxetine, fluvoxamine, citalopram, venlafaxine, escitalopram and sertraline [50].
The data looking at the risk of hyponatremia associated with the use of serotonin–norepi-
nephrine reuptake inhibitors (SNRIs) are even more limited. Most studies have found inci-
dence rates of hyponatremia comparable to the ones reported for SSRIs. Incidence figures for 
mirtazapine and tricyclic antidepressants (TCAs) appear to be lower [46, 51].
The mechanisms of antidepressants induced hyponatremia remain incompletely elucidated, 
but these agents can act by either increasing the release of antidiuretic hormone (ADH) or 
increasing the sensitivity to ADH resulting in a clinical picture similar to the syndrome 
of inappropriate secretion of ADH [12]. It must be clarified that the precise mechanism is 
not known but today it is known that antidepressants are thought to cause the syndrome 
of inappropriate antidiuretic hormone release (SIADH) by direct or indirect stimulation of 
vasopressin release from the posterior pituitary gland. SIADH can be produced by multiple 
causes (hyponatremia with plasma hyposmolality and increased urinary excretion of sodium, 
increase in urinary osmolality, hypotension, heart failure, nephropathy, liver disease…) and 
lead to retention of water and to hyponatremia [52]. The prevalence of SIADH in patients using 
antidepressants has been described in several case reports and a case series and is estimated to 
occur in five of every 1000 patients treated per year [44, 46, 53–54]. If we take into account the 
genetic factor, it is known that most antidepressants are metabolized by the hepatic enzyme 
cytochrome P450 2D6 (CYP2D6), which is highly polymorphic with >60 variant alleles (http://
www.cypalleles.ki.se). In case of individuals carrying two functional CYP2D6 alleles (*1, *2) 
have “normal” enzyme activity and are classified as extensive metabolizers. However, 5–10% 
of the population lack enzyme activity due to inheritance of two nonfunctional alleles (*3, *4, 
*5, *6) and form the so-called poor metabolizers. CYP2D6*4 is the most common variant allele 
in Caucasians (allele frequency of 20%) [55]. Poor metabolizers have higher plasma concentra-
tions of antidepressants metabolized by CYP2D6 and are therefore more likely to suffer from 
adverse drug events [56]. It has been hypothesized that hyponatraemia or low serum sodium 
concentration may be one of these adverse events [57]. This review evaluated the literature on 
association of hyponatremia and the different families of antidepressants.
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4.1. SSRI: selective serotonin reuptake inhibitors
The phenomenon of recurrent hyponatremia induced by the use of SSRI has been described 
in the literature by some authors in subjects who were exposed to it.
Sertraline: In 2013 there were over 41 million prescriptions, making it the most prescribed 
antidepressant and second most prescribed psychiatric medication in the United States [58] 
and is used for a number of conditions. There are many publications with patient cases that 
take this treatment and suffer from hyponatremia [59, 60].
Paroxetine: Paroxetine is primarily used for many mental disorders, has a well-known dis-
continuation syndrome and shares many of the common adverse effects of SSRIs such as 
hyponatremia [61–63].
Fluoxetine: It is a widely used antidepressant, with a multitude of indications and has been 
assessed as the most effective and safe medicine needed in a health system [64]. There are 
many cases of patients with hyponatremia taking this treatment [65].
Citalopram: This antidepressant has a good anxiolytic profile but some cases of hyponatremia 
were recorded [66, 67].
Escitalopram: Is the (S)-stereoisomer of the earlier medication citalopram, used in clinical prac-
tice and is related with cases of hyponatremia [68, 69].
Fluvoxamine: Antidepressant with some uses and some analgesic properties. Many cases of 
hyponatremia were related [70, 71].
4.2. SNRI: serotonin-norepinephrine reuptake inhibitors
Data looking at the risk of hyponatremia associated with the use of SNRIs are even more 
limited but some cases were described.
Venlafaxine: Drug widely used in daily clinical practice, with indications for mental disorders 
and painful pathology. Cases of hyponatremia were registered [72–74].
Duloxetine: Recommended as a first line agent for the treatment of chemotherapy-induced 
neuropathy and for fibromyalgia in the presence of mood disorders, in addition to other dis-
orders. There are patient cases that take this treatment and suffer from hyponatremia [75, 76].
Desvenlafaxine: Desvenlafaxine is a synthetic form of the major active metabolite of venlafax-
ine and some cases of hyponatremia were registered [77].
4.3. Mirtazapine
It has noradrenergical and specific serotonergical antidepressant effect and it is more likely 
to cause weight gain and sleepiness than other treatments. Some cases of hyponatremia were 
described [14, 53–55], however, this antidepressant has not been associated with hyponatre-
mia in all cases or with less power of association to this side effect [46, 49, 53, 60, 76, 78].




Is a norepinephrine-dopamine reuptake inhibitor (NDRI) primarily used as an antidepressant 
and smoking cessation aid and related with cases of hyponatremia [79, 80], but less than other 
antidepressants and that does not happen in all cases [51, 61].
4.5. Tricyclic antidepressants
Discovered in the early 1950s, they have number of uses, many of their side effects may be 
related to the antimuscarinic properties and cases of hyponatremia were registered [81], but 
with fewer registered cases than with other antidepressants [47, 49, 82].
4.6. Vortioxetine
New antidepressant so-called serotonin modulator and stimulator and two cases of patients 
with hyponatremia were registered [83].
4.7. Trazodone
Is a serotonin antagonist and reuptake inhibitor that is widely used for the treatment of 
depression and insomnia. We found controversial results for relationship between trazodone 
and hyponatremia: case reports in patients on treatment [84], some cases were reported in 
overdose [85] or articles which describe less power of association to this side effect [51].
4.8. Agomelatine
Agomelatine is a potent agonist at melatonin receptors and an antagonist at serotonin-2C 
(5-HT2C) receptors. Given the limited references of hyponatremia associated with agomela-
tine, it has been postulated as a therapeutic alternative in those patients with risk or a history 
of hyponatremia that require antidepressant treatment [5].
4.9. Mianserine
Mianserin is a tetracyclic antidepressant with serotonergic (5HT2, 5HT1c), histaminergic and 
adrenergic (α1,α2) inhibitory activity. Some studies report that the association of hyponatre-
mia and mianserin is low [86].
5. Antiepileptics
Epilepsy is a group of neurological disorders characterized by epileptic seizures. It is estimated 
that nearly 40 million people have epilepsy [86], with differences between countries and age 
groups. The median incidence of epilepsy is around 50.4/100,000/year: 45.0 for high-income 
countries and 81.7 for low- and middle-income countries [87]. Incidence is highest in old age 
(>60 years of age), with an estimated 60–135 new cases per 100,000 older adults each year 
[87]. Antiepileptics are, usually, initiated as monotherapy for the treatment of epilepsy [88]. 
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However, these drugs are also often used in treatment of nonepileptic conditions such as pain 
and psychiatric disorders, for this reason it is very common in clinical practice that we find 
antiepileptics associated with other drugs [89].
As with antidepressants, many cases of hyponatremia are associated with the use of anti-
epileptic drugs and have been reported and published. However, there are great differences 
between them [90]. Besides all this, it is important to differentiate cases of antiepileptic that 
induce asymptomatic hyponatremia and can be easily corrected [91] from cases of severe or 
symptomatic hyponatremia. Last ones are associated with various types of neurological dam-
age: seizures, altered mentality, brain stem herniation, death, etc., [92]. Because hyponatremia 
frequently goes undiagnosed and untreated with associated risks, next we will talk about the 
effect of different antiepileptics in this electrolyte abnormality.
5.1. Phenytoin
This drug was approved by the FDA in 1953. It works by blocking voltage-sensitive sodium 
channels. It is one of the most used and affordable antiepileptics, with several presentations. 
Some cases of hyponatremia related to the use of this drug have been described [93], but with 
less intensity than with other antiepileptic drugs [94].
5.2. Carbamazepine
Is used primarily in the treatment of epilepsy, neuropathic pain, schizophrenia along with 
other medications and as a second line agent in bipolar disorder. Carbamazepine is on the 
World Health Organization’s List of Essential Medicines, the most effective and safe medi-
cines needed in a health system World Health Organization [70]. It has sodium channel block-
ing effect. There are many publications with patient cases that take this treatment and suffer 
from hyponatremia, so it is one of the antiepileptics most frequently associated with this side 
effect [90, 93, 95–97].
5.3. Oxcarbazepine
Is a structural derivative of carbamazepine and acts by blocking voltage-sensitive sodium 
channels. Its use can reduce the occurrence of epileptic episodes, and in psychiatry, has been 
shown to improve mood (option for add-on therapy in the treatment of bipolar disorder) and 
reduce anxiety. There is approximately a 25–30% chance of cross-reactivity between carbam-
azepine and oxcarbazepine. Number of cases of hyponatremia have been recorded with this 
treatment and with greater strength of association [49, 84, 90, 92, 98, 99].
5.4. Eslicarbazepine acetate
The active component, eslicarbazepine, stabilizes the inactive state of voltage-gated sodium 
channels (same mechanism of action as oxcarbazepine). This new antiepileptic has potential 
uses for the treatment of trigeminal neuralgia and bipolar disorder. Cases of hyponatremia 
were recorded [91, 100, 101].




Its therapeutic activity and medical indications are very extensive, probably related to mul-
tireceptorial effects: voltage-gated sodium channels, GABA-A, AMPA/kainate, high-voltage-
activated calcium channels and carbonic anhydrase isoenzymes. Some cases of hyponatremia 
are related [85], but with less frequency than with other antiepileptic drugs [102].
5.6. Lamotrigine
Is a sodium channel blocking drug (inhibits voltage-sensitive sodium channels), suppress the 
release of glutamate and aspartate (two dominant excitatory neurotransmitters) and blocks 
L-, N-, and P- type calcium channels, among other receptor effects. It is used in several neuro-
logical and psychiatric disorders and patients with hyponatremia has been notified [90, 103].
5.7. Valproate
Acts through blockade of voltage-gated sodium channels and increased brain levels of 
gamma-aminobutyric acid (GABA). It is used as primary option to treat epilepsy, bipolar dis-
order and to prevent migraine headaches, and is included in the World Health Organization’s 
List of Essential Medicines, the most effective and safe medicines needed in a health system 
[64]. Many cases of hyponatremia with Valproate’s treatment were identified [90, 93, 104–106].
5.8. Gabapentin
Is used primarily to treat seizures and neuropathic pain, and is commonly used to treat anxi-
ety and other disorders. Gabapentin bind to the α2δ-1 subunit of voltage-gated calcium chan-
nels, interacts with NMDA receptors, protein kinase C and inflammatory cytokines. There is 
little relationship between hyponatremia and the use of this drug [90].
5.9. Levetiracetam
This antiepileptic is used to treat epilepsy and different types of seizures. It also associates a 
multitude of indications for its use: Tourette syndrome, anxiety disorder, neuropathic pain… 
It acts as a neuromodulator binding to a synaptic vesicle glycoprotein (SV2A) and by inhib-
iting presynaptic calcium channels. Association of some cases of hyponatremia and use of 
levetiracetam has been documented [90, 107].
5.10. Pregabalin
It is useful when added to other treatments for many indications. It is an analog of GABA and 
increases the density of GABA transporter proteins, the rate of functional GABA transport 
and the extracellular GABA concentrations. Few cases of hyponatremia with use of pregaba-
lin were reported [108].
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6. Conclusions
Hyponatremia is a frequent clinical situation in clinical practice, both in outpatient and inpa-
tient settings. Clinical manifestations have a broad spectrum with effect on different indica-
tors such as morbidity and mortality. Nevertheless, this side effect is avoidable and reversible. 
Given the wide use of psychotropic drugs (antidepressants, antipsychotics and antiepileptics) 
and its current growing use, it is important to know those pharmacological options with lower 
risk of hyponatremia such as bupropion, trazodone, mianserin, pregabalin or gabapentin.
We have seen that etiology of hyponatremia is multifactorial and involves pharmacological 
origin (increase in the production or potentiation of the effects of antidiuretic hormone, altera-
tion of the homeostasis of sodium and water), but many other factors such as advanced age, 
associated pathologies, female sex, weight or use of concomitant drugs also contribute to the 
development of hyponatremia. It is important to identify vulnerable patients and to measure 
sodium levels frequently, especially in the first few days after initiating treatment to help 
prevent or correct hyponatremia and its undesirable effects.
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